#1 Clinical Trials Search in Europe

Cobimetinib

Cobimetinib is an investigational drug being studied in clinical trials for its potential to treat a variety of medical conditions. This article summarizes key information about ongoing clinical trials using cobimetinib, including its applications, dosing, and preliminary findings. The trials are exploring cobimetinib’s efficacy and safety in treating conditions such as histiocytic disorders, arteriovenous malformations, rare tumors, and certain types of cancer.

Table of Contents

What is Cobimetinib?

Cobimetinib is a medication used in the treatment of various cancers and other medical conditions. It’s also known by several other names, including Cotellic, GDC-0973, RO5514041, and XL518[1][2]. This drug belongs to a class of medications called MEK inhibitors, which work by blocking certain proteins involved in cancer cell growth[3].

How Cobimetinib Works

Cobimetinib works by targeting a specific protein called MEK (Mitogen-activated protein kinase). In many cancers, especially those with a mutation in a gene called BRAF, the MEK protein is overactive, leading to uncontrolled cell growth. By inhibiting MEK, cobimetinib helps to slow down or stop the growth of cancer cells[3][4].

In some cases, cobimetinib is used in combination with other drugs, particularly vemurafenib, which targets the BRAF protein. This combination therapy can be more effective in treating certain types of cancer, such as melanoma with a BRAF V600 mutation[5].

Conditions Treated with Cobimetinib

Cobimetinib is used to treat various conditions, including:

  • Malignant Melanoma: A type of skin cancer, particularly when it has spread to other parts of the body (metastatic) and has a specific genetic mutation called BRAF V600[5].
  • Histiocytic Disorders: A group of rare diseases that involve an overgrowth of certain types of immune cells[6].
  • Langerhans Cell Histiocytosis (LCH): A rare disorder where certain immune cells build up in various organs[4].
  • Erdheim-Chester Disease: A rare form of non-Langerhans cell histiocytosis[4].
  • Arteriovenous Malformations: Abnormal connections between arteries and veins[7].
  • Chronic Myelomonocytic Leukemia (CMML): A type of blood cancer[8].

How Cobimetinib is Administered

Cobimetinib is typically taken orally in the form of tablets or a liquid suspension. The dosage and schedule can vary depending on the condition being treated and the patient’s individual needs. Common dosing schedules include:

  • 60 mg once daily for 21 days, followed by a 7-day break (28-day cycle)[5].
  • 60 mg once daily for 28 days continuously[4].

Your doctor will determine the best dosing schedule for your specific situation. It’s important to take cobimetinib exactly as prescribed and to inform your healthcare provider of any side effects you experience[9].

Potential Side Effects

Like all medications, cobimetinib can cause side effects. Some of the most common side effects include:

  • Diarrhea
  • Nausea and vomiting
  • Rash or skin reactions
  • Fatigue
  • Fever
  • Changes in liver function tests
  • Vision problems

More serious side effects can occur, although they are less common. These may include heart problems, severe skin reactions, and eye problems. It’s crucial to report any side effects to your healthcare provider promptly[5][9].

Ongoing Research and Future Potential

Researchers continue to study cobimetinib for its potential in treating various conditions. Some areas of ongoing research include:

  • Combination therapy with other drugs for different types of cancer[10].
  • Treatment of rare diseases like histiocytic disorders[6][4].
  • Use in pediatric patients with solid tumors[2].
  • Treatment of arteriovenous malformations[7].

These ongoing studies aim to expand our understanding of how cobimetinib can be used effectively and safely in various medical conditions[10].

Aspect Details
Drug Name Cobimetinib (also known as GDC-0973, XL518, Cotellic)
Mechanism of Action MEK inhibitor, blocks cell growth signaling
Administration Oral (tablets or suspension)
Common Dosing Schedule 21 days on, 7 days off in 28-day cycles
Conditions Studied Histiocytic disorders, Langerhans cell histiocytosis, arteriovenous malformations, rare tumors, chronic myelomonocytic leukemia, various cancers
Primary Outcomes Measured Overall response rate, progression-free survival, safety, tolerability, pharmacokinetics
Trial Phases Phase I, II, and Ib studies
Combination Therapies Some trials combine cobimetinib with other drugs like atezolizumab, vemurafenib, or onartuzumab

FAQ

  • What is cobimetinib and how does it work? Cobimetinib is an investigational drug that blocks the activity of a protein called MEK, which is involved in cell growth signaling. It is designed to inhibit abnormal cell growth in certain diseases and cancers.
  • What conditions are being studied with cobimetinib in clinical trials? Clinical trials are exploring cobimetinib's potential in treating various conditions, including histiocytic disorders, Langerhans cell histiocytosis, arteriovenous malformations, rare tumors, chronic myelomonocytic leukemia, and certain types of cancer.
  • How is cobimetinib administered in these trials? Cobimetinib is typically administered orally, either as tablets or a liquid suspension. The common dosing schedule is 21 days on treatment followed by a 7-day break in a 28-day cycle.
  • What are some of the primary outcomes being measured in these trials? Primary outcomes often include overall response rate, progression-free survival, safety and tolerability, and pharmacokinetic measures such as maximum concentration in the blood.
  • Are there any common side effects of cobimetinib observed in these trials? While specific side effects are not detailed in the provided information, the trials are closely monitoring for adverse events and dose-limiting toxicities to assess the safety profile of cobimetinib.

Ongoing Clinical Trials on Cobimetinib

  • Study of Ginisortamab with Nab-Paclitaxel and Gemcitabine or MEK Inhibitor for Patients with Metastatic Pancreatic Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany Norway Spain

  • Study of cobimetinib and atezolizumab combination therapy in children and adults with advanced or metastatic soft tissue sarcoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Norway

  • Study of Vemurafenib, Cobimetinib, and Atezolizumab for Patients with High-Risk, Surgically Removable BRAF Mutated and Wild-Type Melanoma

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of Drug Combination for Advanced Cancer Patients with Known Molecular Profile – FINPROVE Study

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study of drug combination in patients with advanced cancer based on genomic profiling – ProTarget Danish nationwide trial

    Recruiting

    2 1 1 1
    Investigated drugs:
    Denmark

  • Study of Obinutuzumab, Vemurafenib, and Cobimetinib for Hairy Cell Leukemia in Patients Previously Treated with Purine Analogs or Unfit for Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on the Effectiveness and Safety of Cyclophosphamide Monohydrate and Drug Combination for Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Italy Spain

  • Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Greece Hungary +5

Glossary

  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.
  • Dose-limiting toxicity: Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose.
  • Maximum tolerated dose: The highest dose of a drug that does not cause unacceptable side effects.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Overall response rate: The proportion of patients whose cancer shrinks or disappears after treatment.
  • Histiocytic disorders: A group of diseases caused by the abnormal accumulation or behavior of certain immune cells called histiocytes.
  • Arteriovenous malformation: An abnormal connection between arteries and veins, bypassing the capillary system.
  • Chronic myelomonocytic leukemia: A type of cancer that starts in blood-forming cells of the bone marrow and invades the blood.

References

  1. https://clinicaltrials.gov/study/NCT02136524
  2. https://clinicaltrials.gov/study/NCT02639546
  3. https://clinicaltrials.gov/study/NCT01974258
  4. https://clinicaltrials.gov/study/NCT04079179
  5. https://clinicaltrials.gov/study/NCT01271803
  6. https://clinicaltrials.gov/study/NCT02649972
  7. https://clinicaltrials.gov/study/NCT05125471
  8. https://clinicaltrials.gov/study/NCT04409639
  9. https://clinicaltrials.gov/study/NCT01249131
  10. https://clinicaltrials.gov/study/NCT03108131